An Open single center arm clinical study of Anti-CD30 CAR-T therapy for relapsed, refractory and high-risk CD30+ Lymphoproliferative diseases
Latest Information Update: 05 Jan 2023
At a glance
- Drugs Anti CD30 chimeric antigen receptor T cell therapy Wuhan Bio Raid Biotechnology (Primary)
- Indications Lymphoma
- Focus Adverse reactions
Most Recent Events
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 08 Jul 2019 New trial record